The inhibitory effects of 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone on human colon cancer cells

Molecular Nutrition and Food Research

Volumn 55, Issue 10, 2011, Pages 1523-1532

  Qiu, Peiju ^a,b   Guan, Huashi ^b   Dong, Ping ^a   Guo, Shanshan ^a   Zheng, Jinkai ^a   Li, Shiming ^c   Chen, Yun ^d   Ho, Chi Tang ^c   Pan, Min Hsiung ^e   Mcclements, David Julian ^a   Xiao, Hang ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b OCEAN UNIVERSITY OF CHINA   (China)

^c RUTGERS UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e NATIONAL KAOHSIUNG UNIVERSITY OF APPLIED SCIENCES   (Taiwan)

Author keywords

Catenin; 5 Hydroxy 3,6,7,8,3',4' hexamethoxyflavone; Angiogenesis; EGFR; K Ras

Indexed keywords

5 HYDROXY 3,6,7,8,3',4' HEXAMETHOXYFLAVONE; 5-HYDROXY-3,6,7,8,3',4'-HEXAMETHOXYFLAVONE; ANTINEOPLASTIC AGENT; BETA CATENIN; CADHERIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; ONCOPROTEIN; REACTIVE OXYGEN METABOLITE;

ARTICLE; COLON TUMOR; DOSE RESPONSE; DRUG SCREENING; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BETA CATENIN; CADHERINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONES; HUMANS; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; ONCOGENE PROTEIN V-AKT; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

CITRUS;

EID: 80053912923     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201100070     Document Type: Article

References (47)

1. Jemal, A., Siegel, R., Ward, E., Murray, T. et al., Cancer statistics, 2007. CA - Cancer J. Clin. 2007, 57, 43-66.
2. Janakiram, N. B., Rao, C. V., Molecular markers and targets for colorectal cancer prevention. Acta Pharmacol. Sin. 2008, 29, 1-20.
3. Smith, G., Carey, F. A., Beattie, J., Wilkie, M. J. et al., Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer. Proc. Natl. Acad. Sci. USA 2002, 99, 9433-9438.
4. Giaretti, W., Venesio, T., Sciutto, A., Prevosto, C., et al., Near-diploid and near-triploid human sporadic colorectal adenocarcinomas differ for KRAS2 and TP53 mutational status. Genes Chromosomes Cancer 2003, 37, 207-213.
5. Bos, J. L., Fearon, E. R., Hamilton, S. R., Verlaan-de Vries, M., et al., Prevalence of ras gene mutations in human colorectal cancers. Nature 1987, 327, 293-297.
6. Forrester, K., Almoguera, C., Han, K., Grizzle, W. E., Perucho, M., Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987, 327, 298-303.
7. Andreyev, H. J., Norman, A. R., Cunningham, D., Oates, J. R., Clarke, P. A., Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J. Natl. Cancer Inst. 1998, 90, 675-684.
8. Messa, C., Russo, F., Caruso, M. G., Di Leo, A., EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 1998, 37, 285-289.
9. Porebska, I., Harlozinska, A., Bojarowski, T., Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000, 21, 105-115.
10. Wheeler, D. L., Dunn, E. F., Harari, P. M., Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010, 7, 493-507.
11. Jiang, Y., Kimchi, E. T., Staveley-O'Carroll, K. F., Cheng, H., Ajani, J. A., Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer 2009, 115, 3609-3617.
12. Van Cutsem, E., Kohne, C. H., Hitre, E., Zaluski, J. et al., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009, 360, 1408-1417.
13. Lievre, A., Bachet, J. B., Le Corre, D., Boige, V. et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66, 3992-3995.
14. Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., et al., Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br. J. Cancer 2007, 96, 1166-1169.
15. De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M. et al., KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 2008, 19, 508-515.
16. Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E. et al., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 1626-1634.
17. Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J. et al., K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359, 1757-1765.
18. Segditsas, S., Tomlinson, I., Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006, 25, 7531-7537.
19. Sakamoto, K., Maeda, S., Targeting NF-kappaB for colorectal cancer. Exp. Opin. Ther. Targets 2010, 14, 593-601.
20. Vaiopoulos, A. G., Papachroni, K. K., Papavassiliou, A. G., Colon carcinogenesis: learning from NF-kappaB and AP-1. Int. J. Biochem. Cell Biol. 2010, 42, 1061-1065.
21. Cheng, K. W., Wong, C. C., Wang, M., He, Q. Y., Chen, F., Identification and characterization of molecular targets of natural products by mass spectrometry. Mass Spectrom. Rev. 2010, 29, 126-155.
22. Hong, W. K., Sporn, M. B., Recent advances in chemoprevention of cancer. Science 1997, 278, 1073-1077.
23. Rudolf, E., Andelova, H., Cervinka, M., Polyphenolic compounds in chemoprevention of colon cancer - targets and signaling pathways. Anticancer Agents Med. Chem. 2007, 7, 559-575.
24. Qiu, P., Dong, P., Guan, H., Li, S. et al., Inhibitory effects of 5-hydroxy polymethoxyflavones on colon cancer cells. Mol. Nutr. Food Res. 2010, 54, S244-S252.
25. Qiu, P., Guan, H., Dong, P., Li, S. et al., The p53-, Bax- and p21-dependent inhibition of colon cancer cell growth by 5-hydroxy polymethoxyflavones. Mol. Nutr. Food Res. 2011, 55, 613-622.
26. Xiao, H., Yang, C. S., Li, S., Jin, H. et al., Monodemethylated polymethoxyflavones from sweet orange (Citrus sinensis) peel inhibit growth of human lung cancer cells by apoptosis. Mol. Nutr. Food Res. 2009, 53, 398-406.
27. Pan, M. H., Lai, Y. S., Lai, C. S., Wang, Y. J. et al., 5-Hydroxy-3, 6, 7, 8, 3', 4'-hexamethoxyflavone induces apoptosis through reactive oxygen species production, growth arrest and DNA damage-inducible gene 153 expression, and caspase activation in human leukemia cells. J. Agric. Food Chem. 2007, 55, 5081-5091.
28. Sergeev, I. N., Li, S., Colby, J., Ho, C. T., Dushenkov, S., Polymethoxylated flavones induce Ca(2+)-mediated apoptosis in breast cancer cells. Life Sci. 2006, 80, 245-253.
29. Sergeev, I. N., Ho, C. T., Li, S., Colby, J., Dushenkov, S., Apoptosis-inducing activity of hydroxylated polymethoxyflavones and polymethoxyflavones from orange peel in human breast cancer cells. Mol. Nutr. Food Res. 2007, 51, 1478-1484.
30. Chen, Y., Leal, A. D., Patel, S., Gorski, D. H., The homeobox gene GAX activates p21WAF1/CIP1 expression in vascular endothelial cells through direct interaction with upstream AT-rich sequences. J. Biol. Chem. 2007, 282, 507-517.
31. Li, S., Lo, C. Y., Ho, C. T., Hydroxylated polymethoxyflavones and methylated flavonoids in sweet orange (Citrus sinensis) peel. J. Agric. Food Chem. 2006, 54, 4176-4185.
32. Wang, Z., Li, S., Jonca, M., Lambros, T. et al., Comparison of supercritical fluid chromatography and liquid chromatography for the separation of urinary metabolites of nobiletin with chiral and non-chiral stationary phases. Biomed. Chromatogr. 2006, 20, 1206-1215.
33. Park, H. J., Kong, D., Iruela-Arispe, L., Begley, U. et al., 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ. Res. 2002, 91, 143-150.
34. Chen, Y., Gorski, D. H., Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008, 111, 1217-1226.
35. Gorski, D. H., Leal, A. J., Inhibition of endothelial cell activation by the homeobox gene Gax. J. Surg. Res. 2003, 111, 91-99.
36. Patel, S., Leal, A. D., Gorski, D. H., The homeobox gene Gax inhibits angiogenesis through inhibition of nuclear factor-kappaB-dependent endothelial cell gene expression. Cancer Res. 2005, 65, 1414-1424.
37. Conacci-Sorrell, M., Zhurinsky, J., Ben-Ze'ev, A., The cadherin-catenin adhesion system in signaling and cancer. J. Clin. Invest. 2002, 109, 987-991.
38. Kongkanuntn, R., Bubb, V. J., Sansom, O. J., Wyllie, A. H., Harrison, D. J., Clarke, A. R., Dysregulated expression of beta-catenin marks early neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 deficient mice. Oncogene 1999, 18, 7219-7225.
39. Perl, A. K., Wilgenbus, P., Dahl, U., Semb, H., Christofori, G., A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998, 392, 190-193.
40. Aberle, H., Schwartz, H., Kemler, R., Cadherin-catenin complex: protein interactions and their implications for cadherin function. J. Cell. Biochem. 1996, 61, 514-523.
41. Orsulic, S., Huber, O., Aberle, H., Arnold, S., Kemler, R., E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J. Cell. Sci. 1999, 112, 1237-1245.
42. Mayer, A., Takimoto, M., Fritz, E., Schellander, G. et al., The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993, 71, 2454-2460.
43. Shen, H. M., Tergaonkar, V., NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009, 14, 348-363.
44. Basseres, D. S., Baldwin, A. S., Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25, 6817-6830.
45. Cavallaro, U., Christofori, G., Molecular mechanisms of tumor angiogenesis and tumor progression. J. Neurooncol. 2000, 50, 63-70.
46. Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1, 27-31.
47. Haas, T. L., Milkiewicz, M., Davis, S. J., Zhou, A. L. et al., Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. Am. J. Physiol. Heart Circ. Physiol. 2000, 279, H1540-H1547.